B.Riley reiterates Buy on 4D Molecular stock, cites trial design
B.Riley reiterated a Buy rating and $37.00 price target on 4D Molecular Therapeutics (FDMT), citing trial design and potential for its gene therapy candidate 4D-150. The company's market cap is $791 million, with shares up 91% year-to-date. Analysts highlight strong cash position, upcoming trial readouts, and potential adoption in wet AMD and diabetic macular edema.
How this was made
The 30-second read
Why it matters
Analyst upgrades collectively raise expectations, but no new clinical data is disclosed.
Market read
The coverage may prompt modest buying pressure, but impact is limited without fresh trial data.
What to watch
Trial results for 4FRONT and 4SIGHT are still pending and could reverse sentiment.
Background
The article aggregates recent analyst upgrades and price targets for 4D Molecular Therapeutics, highlighting its cash position and upcoming investor day.
Ticker impact
B.Riley reiterated a Buy rating and set a $37 price target for 4D Molecular Therapeutics, adding to recent analyst upgrades.
potential upside as market prices in the new $37 target
Multiple analysts have raised targets and upgraded the stock, indicating growing confidence in the pipeline.
Market effects
Positive sentiment may spill over to other gene‑therapy biotech stocks.
Limited to US biotech sector.
Low, confined to niche therapeutic area.
Counterpoint
Upgrades may be premature without upcoming trial readouts; price could be overvalued.
Key entities
- company4D Molecular Therapeutics
Biotech firm developing gene‑therapy candidates for eye diseases.
- analystB.Riley
Equity analyst who reiterated a Buy rating and $37 target.
